Full Text View
Tabular View
Study Results
Related Studies
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders (PANDA)
This study has been completed.
Study NCT00830115   Information provided by Nycomed: A Takeda Company

First Received on January 13, 2009.   Last Updated on May 4, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sleep Disorders
Non-Erosive Reflux Disease
Gastroesophageal Reflux Disease
Additional conditions recognized in this trial
Gastroesophageal Reflux
Parasomnias
More general conditions related to this trial
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Interventions listed in this trial
Pantoprazole
More general drug interventions related to this trial
Anti-Ulcer Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Proton Pump Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Nycomed: A Takeda Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services